Tirzepatide
Also known as: Tirzepatide (GIP/GLP-1 dual receptor agonist — Mounjaro, Zepbound)
Tirzepatide is a unimolecular dual GIP and GLP-1 receptor agonist with a half-life of approximately 5 days, enabling once-weekly subcutaneous dosing. It is FDA-approved as Mounjaro for type 2 diabetes (2022), Zepbound for chronic weight management in adults with obesity or overweight with a weight-related comorbidity (2023), and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity (2024). It carries a BOXED WARNING for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Pricing for Tirzepatide
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
Average price
$6.89/mg
range $0.00–$93.33/mg
Sellers
73
from $0.00
45-day trend
+25.5%
vs 45-day avg $/mg
68 of 73 sellers have a current price· 48 stale listings hidden (not seen in 7 days)
Top Merit pick
🇺🇸 Peptide Partners99via Disclosed Labs · just now
$2.58/mg -62.6% vs avg$3090
1200mg
- 🇺🇸 Orbitrex Peptides95
via Disclosed Labs · just now
$3.33/mg -51.6% vs avg$200
60mg
99.7% purity 15 COAs - 🇺🇸 Profound Aminos95
via Disclosed Labs · just now
$4.65/mg -32.5% vs avg$186
40mg
- 🇺🇸 Prime Peptides95
via Disclosed Labs · just now
$4.67/mg -32.3% vs avg$280
60mg
- 🇺🇸 Licensed Peptides95
✓ verified at source · 1d ago
$28.50/mg +313.4% vs avg$855
30mg
no purityBuy code MERIT · 5% off - 🇺🇸 Forge Performance Co.94
via Disclosed Labs · just now
$3.33/mg -51.6% vs avg$100
30mg
- 🇺🇸 Riptide Wellness92
via Disclosed Labs · just now
$3.00/mg -56.5% vs avg$180
60mg
no purity - 🇺🇸 Sunrise Bioresearch88
via Disclosed Labs · just now
$2.11/mg -69.3% vs avg$63.40
30mg
100.0% purity 2 COAs - 🇺🇸 Simple Peptide85
via Disclosed Labs · just now
$4.25/mg -38.3% vs avg$425
100mg
- Peptide Supply Co.83
via Disclosed Labs · just now
$0.97/mg -86% vs avg$580
600mg
- 🇺🇸 Blank Peptides81
✓ verified at source · just now
$12.00/mg +74.1% vs avg$120
10mg
99.7% purity 2 COAs - 🇺🇸 OROS Research79
via Disclosed Labs · just now
$14.00/mg +103.1% vs avg$140
10mg
99.0% purity 2 COAs - 🇺🇸 Texpeptide65
✓ verified at source · 1d ago
$6.67/mg -3.3% vs avg$100
15mg
- 🇭🇰 Hkuppeptide50
✓ verified at source · just now
$0.50/mg -92.7% vs avg$10.00
20mg
99.8% purity 1 COA - 🇭🇰 zztai Peptide Ltd43
✓ verified at source · just now
$4.67/mg -32.3% vs avg$280
60mg
100.0% purity 1 COA - 🇺🇸 Alpha PeptidesUnscored
via Disclosed Labs · just now
$1.42/mg -79.5% vs avg$84.99
60mg
no purity - peptidetech.isUnscored
via Disclosed Labs · just now
$2.50/mg -63.7% vs avg$300
120mg
no purity - volterasciences.comUnscored
via Disclosed Labs · just now
$2.67/mg -61.3% vs avg$160
60mg
no purity - optimasupply.isUnscored
via Disclosed Labs · just now
$4.30/mg -37.6% vs avg$430
100mg
no purity - 🇺🇸 NG PeptideUnscored
via Disclosed Labs · just now
$9.67/mg +40.2% vs avg$580
60mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
COAs for Tirzepatide
379 third-party tests across 41 vendors. Each card links to the full report.
For
Tirzepatide
by NG Peptide· batch TRZ20-14
For
Tirzepatide
by Aspire Peptides· batch TR10-032026-1
For
Tirzepatide
by Aspire Peptides· batch TR15-032026-1
For
Tirzepatide
by Orbitrex Peptides· batch 2G30726
For
Tirzepatide
by Ion Peptide· batch ION2T20-06242026
For
Tirzepatide
by Profound Aminos· batch Clear Cap/Bronze Crimp
For
Tirzepatide
by Peptide Partners· batch SPL-4130
For
Tirzepatide
by NG Peptide· batch TRZ30-13
For
Tirzepatide
by Peptide Plugs· batch 005-B-SM
For
Tirzepatide
by NG Peptide· batch TRZ60-04
For
Tirzepatide
by Voltera Sciences· batch TR60.05.28.26
For
Tirzepatide
by EZ Peptides· batch EZP-2P2005162026-04
For
Tirzepatide
by EZ Peptides· batch EZP-2P2005162026-04
For
Tirzepatide
by EZ Peptides· batch EZP-2P3004212026-03
For
Tirzepatide
by EZ Peptides· batch EZP-2P3004212026-03
For
Tirzeppatide
by Reta One Labs· batch TR300626
For
Tirzepatide
by Pepsgpt· batch P-9887337-P
For
Tirzepatide
by Glacier Aminos· batch TIR20GA-04
For
Tirzepatide
by NG Peptide· batch TRZ40-14
For
Tirzepatide
by NG Peptide· batch TRZ20-13
For
Tirzepatide
by NG Peptide· batch TRZ30-12
For
Tirzepatide
by Ion Peptide· batch ION2T60-05042026
For
Tirzepatide
by Alpha Peptides· batch T60-42326428
For
Tirzepatide
by Skye Peptides· batch TZ26-60-003
23 citations indexed for Tirzepatide
Study · 2026
Real-World Comparative Effectiveness of Tirzepatide and Semaglutide for Obesity: A Multicentered Study
Objective To compare the real-world weight loss effectiveness and safety of tirzepatide and semaglutide in patients treated for obesity, including those with prior obesity medication (OM) use.
review · 2026
Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation
Introduction Metabolic diseases, including type 2 diabetes mellitus (T2DM), obesity, dyslipidemia, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), and obstructive sleep apnoea (OSA), are characterized by a complex and interconnected pathophysiological syndrome.
case-report · 2026
Starvation-Type Euglycemic Ketoacidosis After Unsupervised Tirzepatide Use in a Non-Obese, Non-Diabetic Woman
BACKGROUND Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for type 2 diabetes and chronic weight management in adults meeting clinical criteria. Appetite suppression and gastrointestinal intolerance can markedly reduce intake.
Study · 2026
Impact of tirzepatide on systemic arterial stiffness assessed by cardio-ankle vascular index in individuals with obesity complicated by type 2 diabetes: A retrospective cohort study in Japan
Background Tirzepatide, a multi-agonist incretin agent that targets body weight and metabolic parameters, has stronger weight reduction and glycemic control effects than existing agents.
Study · 2026
Tirzepatide Regulates Pacemaker Function by Modulating cAMP and Calcium Dynamics in Human Sinoatrial Node Cells
Study · 2026
Efficacy of tirzepatide versus SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD): a multicenter propensity-matched real-world study
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent condition with significant cardiometabolic and hepatic risks.